vs
MESA LABORATORIES INC（MLAB）とSANDRIDGE ENERGY INC（SD）の財務データ比較。上の社名をクリックして会社を切り替えられます
MESA LABORATORIES INCの直近四半期売上が大きい（$65.1M vs $39.4M、SANDRIDGE ENERGY INCの約1.7倍）。SANDRIDGE ENERGY INCの純利益率が高く（54.9% vs 5.6%、差は49.4%）。MESA LABORATORIES INCの前年同期比売上増加率が高い（3.6% vs 1.1%）。MESA LABORATORIES INCの直近四半期フリーキャッシュフローが多い（$18.0M vs $14.4M）。過去8四半期でSANDRIDGE ENERGY INCの売上複合成長率が高い（14.1% vs 5.1%）
メサラボラトリーズ社は、品質管理、校正、モニタリング向け専門機器及び関連サービスの開発・製造・販売を事業としています。医療、製薬、食品飲料、産業衛生、環境試験分野を中心に、世界中の顧客の規制遵守と運用安全のニーズに応えています。
サンドリッジ・エナジーは、米国中コンチネント地域で炭化水素の探査を手がけるエネルギー企業です。デラウェア州法に基づいて設立され、本社をオクラホマ州オクラホマシティに置いており、北米で活躍する独立系石油ガス生産事業者です。
MLAB vs SD — 直接比較
損益計算書 — Q3 FY2026 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $65.1M | $39.4M |
| 純利益 | $3.6M | $21.6M |
| 粗利率 | 64.2% | — |
| 営業利益率 | 12.2% | 38.5% |
| 純利益率 | 5.6% | 54.9% |
| 売上前年比 | 3.6% | 1.1% |
| 純利益前年比 | 316.6% | 23.1% |
| EPS（希薄化後） | $0.65 | $0.59 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $65.1M | $39.4M | ||
| Q3 25 | $60.7M | $39.8M | ||
| Q2 25 | $59.5M | $34.5M | ||
| Q1 25 | $62.1M | $42.6M | ||
| Q4 24 | $62.8M | $39.0M | ||
| Q3 24 | $57.8M | $30.1M | ||
| Q2 24 | $58.2M | $26.0M | ||
| Q1 24 | $58.9M | $30.3M |
| Q4 25 | $3.6M | $21.6M | ||
| Q3 25 | $2.5M | $16.0M | ||
| Q2 25 | $4.7M | $19.6M | ||
| Q1 25 | $-7.1M | $13.0M | ||
| Q4 24 | $-1.7M | $17.6M | ||
| Q3 24 | $3.4M | $25.5M | ||
| Q2 24 | $3.4M | $8.8M | ||
| Q1 24 | $-254.6M | $11.1M |
| Q4 25 | 64.2% | — | ||
| Q3 25 | 61.5% | — | ||
| Q2 25 | 62.0% | — | ||
| Q1 25 | 61.8% | — | ||
| Q4 24 | 63.3% | — | ||
| Q3 24 | 61.3% | — | ||
| Q2 24 | 64.0% | — | ||
| Q1 24 | 62.1% | — |
| Q4 25 | 12.2% | 38.5% | ||
| Q3 25 | 7.8% | 37.8% | ||
| Q2 25 | 5.1% | 53.7% | ||
| Q1 25 | 2.4% | 28.6% | ||
| Q4 24 | 9.2% | 25.9% | ||
| Q3 24 | 6.1% | 28.3% | ||
| Q2 24 | 9.6% | 23.9% | ||
| Q1 24 | -460.6% | 27.8% |
| Q4 25 | 5.6% | 54.9% | ||
| Q3 25 | 4.1% | 40.1% | ||
| Q2 25 | 8.0% | 56.6% | ||
| Q1 25 | -11.4% | 30.6% | ||
| Q4 24 | -2.7% | 45.1% | ||
| Q3 24 | 5.9% | 84.8% | ||
| Q2 24 | 5.8% | 33.9% | ||
| Q1 24 | -432.2% | 36.7% |
| Q4 25 | $0.65 | $0.59 | ||
| Q3 25 | $0.45 | $0.43 | ||
| Q2 25 | $0.85 | $0.53 | ||
| Q1 25 | $-1.30 | $0.35 | ||
| Q4 24 | $-0.31 | $0.46 | ||
| Q3 24 | $0.63 | $0.69 | ||
| Q2 24 | $0.62 | $0.24 | ||
| Q1 24 | $-47.26 | $0.30 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $29.0M | $111.0M |
| 総負債低いほど良い | $68.4M | — |
| 株主資本純資産 | $186.7M | $510.9M |
| 総資産 | $434.8M | $644.0M |
| 負債/資本比率低いほどレバレッジが低い | 0.37× | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $29.0M | $111.0M | ||
| Q3 25 | $20.4M | $101.2M | ||
| Q2 25 | $21.3M | $102.8M | ||
| Q1 25 | $27.3M | $99.7M | ||
| Q4 24 | $27.3M | $98.1M | ||
| Q3 24 | $24.3M | $92.7M | ||
| Q2 24 | $28.5M | $209.9M | ||
| Q1 24 | $28.2M | $207.0M |
| Q4 25 | $68.4M | — | ||
| Q3 25 | $69.4M | — | ||
| Q2 25 | $70.3M | — | ||
| Q1 25 | $71.3M | — | ||
| Q4 24 | $72.2M | — | ||
| Q3 24 | $73.1M | — | ||
| Q2 24 | $74.1M | — | ||
| Q1 24 | — | — |
| Q4 25 | $186.7M | $510.9M | ||
| Q3 25 | $178.5M | $492.4M | ||
| Q2 25 | $172.5M | $480.2M | ||
| Q1 25 | $159.8M | $464.9M | ||
| Q4 24 | $155.2M | $460.5M | ||
| Q3 24 | $161.5M | $446.8M | ||
| Q2 24 | $150.7M | $424.8M | ||
| Q1 24 | $145.4M | $419.7M |
| Q4 25 | $434.8M | $644.0M | ||
| Q3 25 | $430.4M | $619.0M | ||
| Q2 25 | $435.7M | $602.3M | ||
| Q1 25 | $433.3M | $588.3M | ||
| Q4 24 | $433.3M | $581.5M | ||
| Q3 24 | $454.1M | $565.2M | ||
| Q2 24 | $440.4M | $529.6M | ||
| Q1 24 | $446.8M | $527.4M |
| Q4 25 | 0.37× | — | ||
| Q3 25 | 0.39× | — | ||
| Q2 25 | 0.41× | — | ||
| Q1 25 | 0.45× | — | ||
| Q4 24 | 0.47× | — | ||
| Q3 24 | 0.45× | — | ||
| Q2 24 | 0.49× | — | ||
| Q1 24 | — | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $18.8M | $31.7M |
| フリーキャッシュフロー営業CF - 設備投資 | $18.0M | $14.4M |
| FCFマージンFCF / 売上 | 27.7% | 36.6% |
| 設備投資強度設備投資 / 売上 | 1.1% | 43.8% |
| キャッシュ転換率営業CF / 純利益 | 5.17× | 1.46× |
| 直近12ヶ月FCF直近4四半期 | $37.9M | $41.5M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $18.8M | $31.7M | ||
| Q3 25 | $8.2M | $25.3M | ||
| Q2 25 | $1.9M | $22.9M | ||
| Q1 25 | $12.7M | $20.3M | ||
| Q4 24 | $18.1M | $26.0M | ||
| Q3 24 | $5.3M | $20.8M | ||
| Q2 24 | $10.7M | $11.4M | ||
| Q1 24 | $12.9M | $15.7M |
| Q4 25 | $18.0M | $14.4M | ||
| Q3 25 | $7.1M | $5.9M | ||
| Q2 25 | $884.0K | $7.3M | ||
| Q1 25 | $11.9M | $13.9M | ||
| Q4 24 | $17.3M | $13.2M | ||
| Q3 24 | $3.5M | $10.8M | ||
| Q2 24 | $9.9M | $9.0M | ||
| Q1 24 | $12.3M | $14.6M |
| Q4 25 | 27.7% | 36.6% | ||
| Q3 25 | 11.7% | 14.9% | ||
| Q2 25 | 1.5% | 21.0% | ||
| Q1 25 | 19.2% | 32.7% | ||
| Q4 24 | 27.6% | 33.8% | ||
| Q3 24 | 6.0% | 36.1% | ||
| Q2 24 | 16.9% | 34.5% | ||
| Q1 24 | 21.0% | 48.1% |
| Q4 25 | 1.1% | 43.8% | ||
| Q3 25 | 1.8% | 48.6% | ||
| Q2 25 | 1.7% | 45.2% | ||
| Q1 25 | 1.2% | 15.0% | ||
| Q4 24 | 1.3% | 32.9% | ||
| Q3 24 | 3.1% | 33.3% | ||
| Q2 24 | 1.5% | 9.4% | ||
| Q1 24 | 0.9% | 3.7% |
| Q4 25 | 5.17× | 1.46× | ||
| Q3 25 | 3.32× | 1.58× | ||
| Q2 25 | 0.40× | 1.17× | ||
| Q1 25 | — | 1.56× | ||
| Q4 24 | — | 1.48× | ||
| Q3 24 | 1.54× | 0.82× | ||
| Q2 24 | 3.17× | 1.30× | ||
| Q1 24 | — | 1.41× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
MLAB
| Sterilization And Disinfection Control | $24.9M | 38% |
| Biopharmaceutical Development | $14.4M | 22% |
| Other | $14.1M | 22% |
| Clinical Genomics | $11.8M | 18% |
SD
| Oil Reserves | $19.0M | 48% |
| Natural Gas Reserves | $11.6M | 30% |
| Natural Gas Liquids Reserves | $8.7M | 22% |
